Barbara Weber is President and Chief Executive Officer of Tango Therapeutics, a biotechnology company she began building shortly after joining Third Rock Ventures in March 2015. Barbara has led the company from its inception to a Series A funded start-up and now a publicly traded clinical-stage company with more than 100 employees.
Prior to joining Third Rock Ventures, Barbara was Senior Vice President and Global Head, Oncology Translational Medicine at Novartis from 2009 to 2015 and Vice President, Oncology Discovery and Translational Medicine at GlaxoSmithKline from 2005 to 2009. Prior to joining the pharmaceutical industry, Barbara was Professor of Medicine and Genetics at the University of Pennsylvania, leading a clinical and translational research program in cancer genetics.
Barbara is an elected member of the American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara also has served on the board of directors of both ASCO and AACR. Barbara serves on the board of directors of Revolution Medicines, FogPharma, and OPY Acquisition Corp I.
After earning her Bachelor of Science degree in chemistry from the University of Washington, Barbara graduated from the University of Washington School of Medicine. She completed her residency in internal medicine at Yale University and a fellowship in medical oncology at the Dana-Farber Cancer Institute.